Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2019, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.
Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 6, 70, 22 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 14, 16 and 1 molecules, respectively.
Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Pseudomonas aeruginosa Infections - Overview
Pseudomonas aeruginosa Infections - Therapeutics Development
Pseudomonas aeruginosa Infections - Therapeutics Assessment
Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development
Pseudomonas aeruginosa Infections - Drug Profiles
Pseudomonas aeruginosa Infections - Dormant Projects
Pseudomonas aeruginosa Infections - Discontinued Products
Pseudomonas aeruginosa Infections - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 8: Products under Development by Companies, H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 14: Products under Development by Universities/Institutes, H2 2019
Table 15: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 16: Number of Products by Stage and Target, H2 2019
Table 17: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019
Table 19: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 20: Number of Products by Stage and Route of Administration, H2 2019
Table 21: Number of Products by Stage and Molecule Type, H2 2019
Table 22: Pseudomonas aeruginosa Infections - Pipeline by Acies Bio doo, H2 2019
Table 23: Pseudomonas aeruginosa Infections - Pipeline by Affilogic SAS, H2 2019
Table 24: Pseudomonas aeruginosa Infections - Pipeline by Affinivax Inc, H2 2019
Table 25: Pseudomonas aeruginosa Infections - Pipeline by Agile Sciences Inc, H2 2019
Table 26: Pseudomonas aeruginosa Infections - Pipeline by AGILeBiotics BV, H2 2019
Table 27: Pseudomonas aeruginosa Infections - Pipeline by AiCuris GmbH & Co KG, H2 2019
Table 28: Pseudomonas aeruginosa Infections - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2019
Table 29: Pseudomonas aeruginosa Infections - Pipeline by AlgiPharma AS, H2 2019
Table 30: Pseudomonas aeruginosa Infections - Pipeline by Amicrobe Inc, H2 2019
Table 31: Pseudomonas aeruginosa Infections - Pipeline by AMR Centre Ltd, H2 2019
Table 32: Pseudomonas aeruginosa Infections - Pipeline by Appili Therapeutics Inc, H2 2019
Table 33: Pseudomonas aeruginosa Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2019
Table 34: Pseudomonas aeruginosa Infections - Pipeline by Armata Pharmaceuticals Inc, H2 2019
Table 35: Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2019
Table 36: Pseudomonas aeruginosa Infections - Pipeline by Atterx Biotherapeutics Inc, H2 2019
Table 37: Pseudomonas aeruginosa Infections - Pipeline by Aurora Oncology Inc, H2 2019
Table 38: Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2019
Table 39: Pseudomonas aeruginosa Infections - Pipeline by Biolytx Pharmaceuticals Corp, H2 2019
Table 40: Pseudomonas aeruginosa Infections - Pipeline by Biomendics LLC, H2 2019
Table 41: Pseudomonas aeruginosa Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
Table 42: Pseudomonas aeruginosa Infections - Pipeline by Boston Pharmaceuticals Inc, H2 2019
Table 43: Pseudomonas aeruginosa Infections - Pipeline by Bugworks Research India Pvt Ltd, H2 2019
Table 44: Pseudomonas aeruginosa Infections - Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
Table 45: Pseudomonas aeruginosa Infections - Pipeline by Centauri Therapeutics Ltd, H2 2019
Table 46: Pseudomonas aeruginosa Infections - Pipeline by Combioxin SA, H2 2019
Table 47: Pseudomonas aeruginosa Infections - Pipeline by ContraFect Corp, H2 2019
Table 48: Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC, H2 2019
Table 49: Pseudomonas aeruginosa Infections - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Table 50: Pseudomonas aeruginosa Infections - Pipeline by Destiny Pharma Plc, H2 2019
Table 51: Pseudomonas aeruginosa Infections - Pipeline by Eligochem Ltd, H2 2019
Table 52: Pseudomonas aeruginosa Infections - Pipeline by EnBiotix Inc, H2 2019
Table 53: Pseudomonas aeruginosa Infections - Pipeline by Entasis Therapeutics Inc, H2 2019
Table 54: Pseudomonas aeruginosa Infections - Pipeline by Evaxion Biotech ApS, H2 2019
Table 55: Pseudomonas aeruginosa Infections - Pipeline by Evotec SE, H2 2019
Table 56: Pseudomonas aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Table 57: Pseudomonas aeruginosa Infections - Pipeline by Fedora Pharmaceuticals Inc, H2 2019
Table 58: Pseudomonas aeruginosa Infections - Pipeline by Forge Therapeutics Inc, H2 2019
Table 59: Pseudomonas aeruginosa Infections - Pipeline by Helix BioMedix Inc, H2 2019
Table 60: Pseudomonas aeruginosa Infections - Pipeline by Hsiri Therapeutics LLC, H2 2019
List of Figures
Figure 1: Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
